Cooley advised the underwriters on Biomea Fusion’s $153 million initial public offering of 9,000,000 shares of common stock. J.P. Morgan Securities, Jefferies and Piper Sandler acted as joint book-running managers for the offering. Biomea Fusion, whose securities now trade on the Nasdaq Global Select Market under the symbol BMEA, is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Partners Charlie Kim, Jonie Kondracki and Kristin VanderPas led the Cooley team.
